

2025 年

英文

Tokunaga T, Hirata H, Hitaka Y, Fujii N, Kobayashi K, Hayano T, Asai Y, Shiraishi K. Role of long non-coding RNA leucine-rich repeat containing 75 A-antisense RNA1 in the invasion and progression of renal cell carcinoma.

Oncology Reports. 2025; 53(1):11.

Kobayashi K, Sakano S, Matsumoto H, Yamamoto M, Tsuchida M, Tei Y, Nagao K, Oba K, Kitahara S, Yano S, Yoshihiro S, Yamamoto Y, Ohmi C, Komatsu H, Misumi T, Akao J, Shiraishi K. Prognostic risk score and index including the platelet-to-lymphocyte ratio and lactate dehydrogenase in patients with metastatic or unresectable urothelial carcinoma treated with immune checkpoint inhibitors.

Japanese Journal of Clinical Oncology. 2025; 55(2):148-157.

Shimabukuro T, Tanaka H, Tanabe M, Tokunaga T, Shimizu K, Fujii N, Kobayashi K, Hirata H, Shiraishi K. Long-Term Clinical Outcomes of Radical Prostatectomy Versus Image-Guided and Intensity-Modulated Radiation Therapy for Prostate Cancer: A Retrospective and Comparative Study.

Advances in Urology. 2025; 2025:6412793.

Kobayashi K, Fujii N, Shimizu K, Hitaka Y, Oka S, Nakamura K, Hiroyoshi T, Isoyama N, Hirata H, Shiraishi K. Comparative analysis of oncological outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer utilizing propensity score matching.

Japanese Journal of Clinical Oncology. 2025; 55(3):290-296.

Matsumoto Y, Hitaka Y, Hirata H, Yamamoto Y, Kobayashi K, Isoyama N, Matsubara T, Watanabe K, Mizukami Y, Nakagawa S, Mishima K, Harada K, Shiraishi K. Exploration of predictive factors based on oral and intestinal bacterial flora for treating patients with urothelial carcinoma.

PLoS One. 2025; 20(6):e0324814.

Kobayashi K, Fujii N, Shimizu K, Hitaka Y, Oka S, Nakamura K, Hiroyoshi T, Isoyama N, Hirata H, Shiraishi K. Comparative analysis of oncological outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer utilizing propensity score matching.

Japanese Journal of Clinical Oncology. 2025; 55:290-296.

Kobayashi K, Sakano S, Matsumoto H, Tsuchida M, Tei Y, Nagao K, Oba K, Kitahara S, Yano S, Shiraishi K. The Pretreatment Neutrophil-to-Eosinophil Ratio Can Predict Immune-Related Adverse Events and Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Immune

Checkpoint Inhibitors.

Cureus. 2025; 17(8):e89650.

Shimabukuro T, Tokunaga T, Shimizu K, Fujii N, Kobayashi K, Hiroyoshi T, Hirata H, Shiraishi K. Time to Prostate-Specific Antigen Failure as a Unique Prognosticator of Overall Survival in Biochemically Recurrent Prostate Cancer Patients Undergoing Radical Prostatectomy.

Advances in Urology. 2025; 2025:2961319.

Fujii N, Hirata H, Ban Y, Tokunaga T, Shimizu K, Oka S, Kobayashi K, Shiraishi K. Extracellular vesicle lncRNA AGAP2-AS1 as a non-invasive prognostic biomarker in patients with advanced renal cell carcinoma.

American Journal of Cancer Research. 2025; 15(9):3919-3932.

Kobayashi K, Tokunaga T, Nagao K, Fujikawa K, Oba K, Takai K, Matsumoto H, Sakano S, Shirataki S, Tei Y, Tabara M, Yoshihiro S, Yano S, Ito H, Kitahara S, Ohmi C, Akao J, Shiraishi K. Comprehensive Evaluation of Androgen Receptor Pathway Inhibitors in Metastatic Castration-Sensitive Prostate Cancer: A Multicenter Inverse Probability of Treatment Weighting-Based Study.

Clinical Genitourinary Cancer. 2025; 23(6):102437.

Hirata H, Fujii N, Tokunaga T, Shimizu K, Kobayashi K, Shiraishi K. Prognostic value of the postoperative CALLY index in T1/T2 clear cell renal cell carcinoma

Oncology Letters. 2025; 30(6):584.

Tokunaga T, Kobayashi K, Nagao K, Fujikawa K, Oba K, Takai K, Matsumoto H, Sakano S, Shirataki S, Tei Y, Tabara M, Yoshihiro S, Yano S, Ito H, Kitahara S, Ohmi C, Akao J, Shiraishi K. Refining the CHARTED Classification: Clinical Utility of a Novel Integrated Risk Stratification Model Incorporating Gleason Grade and Biochemical Markers in Japanese Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Prostate. 2025; 85(14):1323-1331.

Fujii N, Hirata H, Ban Y, Oka S, Tokunaga T, Hitaka Y, Shimizu K, Kobayashi K, Isoyama N, Shiraishi K. Extracellular vesicles-derived LncRNA MAFG-AS1 predicts clinical response to pembrolizumab in patients with advanced urothelial carcinoma.

Molecular Biology Reports. 2025; 53(1):23.

Fujii N, Urabe F, Yamamoto S, Inoue K, Kimura T, Shiraishi K. Extracellular vesicles in renal cell

carcinoma: A review of the current landscape and future directions.

Urologic Oncology: Seminars and Original Investigations. 2025; 43(6):370-379.

Oka S, Takii R, Fujimoto M, Nakai A, Shiraishi K. HSF1/HSP25 system protects mitochondria function from heat stress and assists steroidogenesis in MA-10 Leydig cells

Molecular and cellular endocrinology. 2025; 595: e112391

和文

白石晃司. 男性不妊症.

泌尿器外科. 2025;38(特別号) :400-407.

白石晃司.男性不妊症に対する最新の生殖医療と山口大学での試み.

西日本泌尿器科. 2025;87(Suppl2);99-67.

白石晃司. 陰茎絞扼症・嵌頓包茎.

臨床泌尿器科. 2025;79(5):355-360.

白石晃司. 透析患者の性機能障害.

臨床透析. 2025;41(6)627-631.

白石晃司. 実践 LH, FSH およびテストステロン値の解釈.

泌尿器外科. 2025.38(7)566-570.

白石晃司. 男性不妊診療の転換点.

BioClinica. 2025;40 (6):17-22.

白石晃司. ライディッヒ細胞刺激を中心とした非閉塞性無精子症に対する内分泌療法の現状と展望.

日本生殖内分泌学会雑誌. 2025;30:7-12.

白石晃司.男性不妊症：併存疾患や生活習慣との関連.

臨床泌尿器科. 2025;79(12)10301039.

中浜 雄, 北原 誠司, 松山 豪泰, 白石 晃司. 保存的に加療し得た特発性腎梗塞の1例.

西日本泌尿器科. 2025; 88(1)28-33.

白石晃司. その他の尿路性器先天異常.
今日の治療指針 (医学書院) 2025, pp1216.

白石晃司. 男性不妊.
専攻医がおさえておきたい泌尿器疾患 Top30 2025(医学図書出版) 2025, pp 400-407.

白石晃司. テストステロン.
いまさら訊けない! 透析患者検査値のみかた, 考えかた Ver3(中外医学社)2025,pp 201-205.

磯山直仁、白石晃司. 尿路結石症.
尿沈渣レファレンスブック (医学書院) 2025, pp 154-155.

岡真太郎、白石晃司. 男性不妊症治療における薬物療法.
日本 IVF 学会雑誌. 2025:28(1) 6-11.

岡真太郎、白石晃司. 慢性陰嚢痛に対する顕微鏡下精索除神経術
泌尿器外科. 2025:37(3) 218-222.

岡真太郎、白石晃司. 精巣摘除術
小児外科. 2025:57(12) 1277-1280.